辉瑞制药和BioNTech的更新版新冠疫苗获欧洲药品管理局积极意见

英为财情
25 Jul

Investing.com -- 辉瑞制药( Pfizer )(NYSE:PFE)和BioNTech(NASDAQ:BNTX)的LP.8.1适应型单价新冠疫苗已获得欧洲药品管理局人用药品委员会(CHMP)的积极意见。

根据两家公司发布的声明,该推荐适用于6个月及以上年龄的个体。

CHMP的建议现将由欧盟委员会审核,预计欧盟委员会将很快就该更新版疫苗作出最终决定。

本文由人工智能协助翻译。更多信息,请参见我们的使用条款。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10